Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future

被引:20
作者
Baldanti, Fausto [1 ]
Ganguly, Nirmal K. [2 ]
Wang, Guiqiang [3 ]
Moeckel, Martin [4 ]
O'Neill, Luke A. [5 ]
Renz, Harald [6 ,7 ]
dos Santos Ferreira, Carlos Eduardo [8 ]
Tateda, Kazuhiro [9 ]
Van der Pol, Barbara [10 ]
机构
[1] Univ Pavia, Diagnost & Pediat Sci, Pavia, Italy
[2] Indian Council Med Res, New Delhi, India
[3] Peking Univ First Hosp, Ctr Liver Dis, Beijing, Peoples R China
[4] Charite, Berlin, Germany
[5] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin, Ireland
[6] Philipps Univ Marburg, Univ Hosp Giessen & Marburg GmbH, Mol Diagnost, Inst Lab Med & Pathobiochem, Giessen, Germany
[7] IM Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergol, Moscow, Russia
[8] Albert Einstein Hosp, Sao Paulo, Brazil
[9] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[10] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA
关键词
SARS-CoV-2; molecular testing; PCR; point-of-care testing; antigen testing; CYCLE THRESHOLD VALUES; CLINICAL-PERFORMANCE; INFLUENZA ACTIVITY; ANTIGEN TESTS; COVID-19; ANTIBODY; METAANALYSIS; MANAGEMENT; ACCURACY; RNA;
D O I
10.1080/10408363.2022.2045250
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A plethora of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic tests are available, each with different performance specifications, detection methods, and targets. This narrative review aims to summarize the diagnostic technologies available and how they are best selected to tackle SARS-CoV-2 infection as the pandemic evolves. Seven key settings have been identified where diagnostic tests are being deployed: symptomatic individuals presenting for diagnostic testing and/or treatment of COVID-19 symptoms; asymptomatic individuals accessing healthcare for planned non-COVID-19-related reasons; patients needing to access emergency care (symptom status unknown); patients being discharged from healthcare following hospitalization for COVID-19; healthy individuals in both single event settings (e.g. airports, restaurants, hotels, concerts, and sporting events) and repeat access settings (e.g. workplaces, schools, and universities); and vaccinated individuals. While molecular diagnostics remain central to SARS-CoV-2 testing strategies, we have offered some discussion on the considerations for when other tools and technologies may be useful, when centralized/point-of-care testing is appropriate, and how the various additional diagnostics can be deployed in differently resourced settings. As the pandemic evolves, molecular testing remains important for definitive diagnosis, but increasingly widespread point-of-care testing is essential to the re-opening of society.
引用
收藏
页码:445 / 459
页数:15
相关论文
共 142 条
[31]   The Possibility and Cause of Relapse After Previously Recovering From COVID-19: A Systematic Review [J].
Elsayed, Sarah M. ;
Reddy, Mithun K. ;
Murthy, Pooja M. ;
Gupta, Ishita ;
Valiuskyte, Monika ;
Sanchez, Diana F. ;
Diaz, Mark Anthony .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
[32]   Preanalytical Issues and Cycle Threshold Values in SARS-CoV-2 Real-Time RT-PCR Testing: Should Test Results Include These? [J].
Engelmann, Ilka ;
Alidjinou, Enagnon Kazali ;
Ogiez, Judith ;
Pagneux, Quentin ;
Miloudi, Sana ;
Benhalima, Ilyes ;
Ouafi, Mahdi ;
Sane, Famara ;
Hober, Didier ;
Roussel, Alain ;
Cambillau, Christian ;
Devos, David ;
Boukherroub, Rabah ;
Szunerits, Sabine .
ACS OMEGA, 2021, 6 (10) :6528-6536
[33]  
European Center for Disease Prevention and Control, 2021, INF PREV CONTR PREP
[34]  
European Centers for Disease Prevention and Control, 2020, OPT US RAP ANT TESTS
[35]  
European Centre for Disease Prevention and Control, 2021, TEST STRAT SARS COV
[36]  
European Centre for Disease Prevention and Control, 2021, METH DET ID SARS COV
[37]   SARS-CoV-2 testing in low- and middle-income countries: availability and affordability in the private health sector [J].
Faust, Lena ;
Zimmer, Alexandra J. ;
Kohli, Mikashmi ;
Saha, Senjuti ;
Boffa, Jody ;
Bayot, Marlon L. ;
Nsofor, Ifeanyi ;
Campos, Leonel ;
Mashamba-Thompson, Tivani ;
Herrera, Rosa ;
Emeka, Elom ;
Shrestha, Suvesh ;
Ugarte-Gil, Cesar ;
Katamba, Achilles ;
Pambudi, Imran ;
Bichara, David ;
Calderon, Roger I. ;
Ahmadzada, Namatullah ;
Safdar, Muhammad Aamir ;
Nikam, Chaitali ;
Lazari, Carolina dos Santos ;
Hussain, Hamidah ;
Win, Myint Myint ;
Than, Kyaw Zin ;
Ahumibe, Anthony ;
Waning, Brenda ;
Pai, Madhukar .
MICROBES AND INFECTION, 2020, 22 (10) :511-514
[38]  
FDA, 2021, Standard
[39]  
FDA, 2019, COR DIS 2019 TEST BA
[40]  
FDA, 2021, EM US AUTH EUA SUMM